Chandrajit P Raut1,2, Rosalba Miceli3, Dirk C Strauss4, Carol J Swallow5,6, Peter Hohenberger7, Frits van Coevorden8, Piotr Rutkowski9, Marco Fiore10, Dario Callegaro10, Paolo G Casali11, Rick L Haas12, Andrew J Hayes4, Charles Honore13, Amanda J Cannell5,6, Jens Jakob7, Milena Szacht9, Mark Fairweather1,2, Raphael E Pollock14, Sylvie Bonvalot15, Alessandro Gronchi10. 1. Division of Surgical Oncology, Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. 2. Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. 3. Department of Medical Statistics, Biometry and Bioinformatics, IRCCS Foundation National Cancer Institute, Milan, Italy. 4. Department of Surgery, Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom. 5. Department of Surgical Oncology, Mount Sinai Hospital and Princess Margaret Cancer Centre, Toronto, Ontario, Canada. 6. Department of Surgery, University of Toronto, Toronto, Ontario, Canada. 7. Division of Surgical Oncology and Thoracic Surgery, Mannheim University Hospital, Mannheim, Germany. 8. Department of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands. 9. Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland. 10. Department of Surgery, IRCCS Foundation National Cancer Institute, Milan, Italy. 11. Department of Cancer Medicine, IRCCS Foundation National Cancer Institute, Milan, Italy. 12. Department of Radiation Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands. 13. Department of Surgery, Gustave Roussy Institute, Villejuif, France. 14. Division of Surgical Oncology, Department of Surgery, Ohio State University Medical Center, Columbus, Ohio. 15. Department of Surgery, Curie Institute, Paris, France.
Abstract
BACKGROUND: A multi-institutional nomogram for predicting disease-free survival (DFS) and overall survival (OS) in patients with primary retroperitoneal sarcoma (RPS) incorporating relevant prognostic factors not included in the American Joint Committee on Cancer staging system for soft tissue sarcoma has been reported. The authors validated this nomogram with an independent, transatlantic cohort. METHODS: Data from patients with RPS who were undergoing definitive resection at 1 of 6 sarcoma centers in Europe and North America ("validation set") were used to validate a RPS nomogram developed from 3 other centers ("development set"). The nomogram incorporated 6 variables: age, tumor size, grade, histologic subtype, multifocality, and quality of surgery. Nomogram-predicted probabilities were stratified into 6 subgroups and compared with observed outcomes. Discriminative ability was quantified by Harrell C statistics. RESULTS: The validation and development sets included 631 and 523 patients, respectively, all of whom underwent surgical resection at the institutions represented. The 7-year DFS and OS rates for the validation set were 38% (95% confidence interval, 34%-43%) and 58% (95% confidence interval, 53%-63%), respectively. All 6 nomogram variables were found to be independently prognostic. The corrected Harrell C statistics concordance index values for the validation set were 0.69 for DFS and 0.73 for OS, which were similar to those for the development set, suggesting good calibration of the nomogram in the validation cohort. CONCLUSIONS: The RPS nomogram was externally validated using a larger, independent cohort. The nomogram can be generalized to patients undergoing surgery for RPS by specialized sarcoma surgeons at sarcoma centers. The nomogram provides a more individualized and disease-relevant estimation of OS compared with the American Joint Committee on Cancer classification. Cancer 2016;122:1417-1424.
BACKGROUND: A multi-institutional nomogram for predicting disease-free survival (DFS) and overall survival (OS) in patients with primary retroperitoneal sarcoma (RPS) incorporating relevant prognostic factors not included in the American Joint Committee on Cancer staging system for soft tissue sarcoma has been reported. The authors validated this nomogram with an independent, transatlantic cohort. METHODS: Data from patients with RPS who were undergoing definitive resection at 1 of 6 sarcoma centers in Europe and North America ("validation set") were used to validate a RPS nomogram developed from 3 other centers ("development set"). The nomogram incorporated 6 variables: age, tumor size, grade, histologic subtype, multifocality, and quality of surgery. Nomogram-predicted probabilities were stratified into 6 subgroups and compared with observed outcomes. Discriminative ability was quantified by Harrell C statistics. RESULTS: The validation and development sets included 631 and 523 patients, respectively, all of whom underwent surgical resection at the institutions represented. The 7-year DFS and OS rates for the validation set were 38% (95% confidence interval, 34%-43%) and 58% (95% confidence interval, 53%-63%), respectively. All 6 nomogram variables were found to be independently prognostic. The corrected Harrell C statistics concordance index values for the validation set were 0.69 for DFS and 0.73 for OS, which were similar to those for the development set, suggesting good calibration of the nomogram in the validation cohort. CONCLUSIONS: The RPS nomogram was externally validated using a larger, independent cohort. The nomogram can be generalized to patients undergoing surgery for RPS by specialized sarcoma surgeons at sarcoma centers. The nomogram provides a more individualized and disease-relevant estimation of OS compared with the American Joint Committee on Cancer classification. Cancer 2016;122:1417-1424.
Authors: Sarah B Fisher; Yi-Ju Chiang; Barry W Feig; Janice N Cormier; Kelly K Hunt; Keila E Torres; Christina L Roland Journal: Am J Clin Oncol Date: 2019-02 Impact factor: 2.339
Authors: John S A Chrisinger; Tariq Al-Zaid; Emily Z Keung; Cheuk Leung; Heather Y Lin; Christina L Roland; Keila E Torres; Robert S Benjamin; Davis R Ingram; Samia Khan; Neeta Somaiah; Behrang Amini; Barry W Feig; Alexander J Lazar; Wei-Lien Wang Journal: J Surg Oncol Date: 2019-06-17 Impact factor: 3.454
Authors: Carol J Swallow; Dirk C Strauss; Sylvie Bonvalot; Piotr Rutkowski; Anant Desai; Rebecca A Gladdy; Ricardo Gonzalez; David E Gyorki; Mark Fairweather; Winan J van Houdt; Eberhard Stoeckle; Jae Berm Park; Markus Albertsmeier; Carolyn Nessim; Kenneth Cardona; Marco Fiore; Andrew Hayes; Dimitri Tzanis; Jacek Skoczylas; Samuel J Ford; Deanna Ng; John E Mullinax; Hayden Snow; Rick L Haas; Dario Callegaro; Myles J Smith; Toufik Bouhadiba; Silvia Stacchiotti; Robin L Jones; Thomas DeLaney; Christina L Roland; Chandrajit P Raut; Alessandro Gronchi Journal: Ann Surg Oncol Date: 2021-04-14 Impact factor: 4.339
Authors: Edmund K Bartlett; Christina E Curtin; Kenneth Seier; Li-Xuan Qin; Meera Hameed; Sam S Yoon; Aimee M Crago; Murray F Brennan; Samuel Singer Journal: Ann Surg Date: 2021-06-01 Impact factor: 13.787
Authors: J A Livingston; D Bugano; A Barbo; H Lin; J E Madewell; W L Wang; A J Lazar; W W Tseng; C L Roland; B W Feig; R Pollock; A P Conley; R S Benjamin; S Patel; N Somaiah Journal: Sci Rep Date: 2017-09-19 Impact factor: 4.379
Authors: Michael J Nathenson; Constance M Barysauskas; Robert A Nathenson; William F Regine; Nader Hanna; Edward Sausville Journal: World J Surg Oncol Date: 2018-10-11 Impact factor: 2.754